Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy

NCT06554288 is registered in ClinicalTrials.gov with Children's Mercy Hospital Kansas City as lead sponsor.

NCT NCT06554288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06554288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy
Lead sponsor
Children's Mercy Hospital Kansas City
Phase
Phase 1
Overall status
Recruiting
Start date
October 15, 2024
Completion date
December 31, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral palsy, dyskinetic, cerebral palsy, dystonic-rigid, dystonia, dystonia, secondary, genetic predisposition, pediatric disorder, pharmacogenomic drug interaction, trihexyphenidyl adverse reaction